Premium
Ovarian cancer: patterns of care in Victoria during 1993–1995
Author(s) -
Grossi Marisa,
Francis Prudence A,
Quinn Michael A,
Rome Robert M,
Planner Robert S,
Thursfield Vicky J,
Giles Graham G
Publication year - 2002
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2002.tb04616.x
Subject(s) - medicine , referral , cancer registry , ovarian cancer , cohort , cancer , relative survival , population , retrospective cohort study , stage (stratigraphy) , cohort study , gynecology , surgery , family medicine , paleontology , environmental health , biology
Objective: To describe the management of and outcomes in patients with newly diagnosed ovarian cancer during 1993, 1994 and 1995 in Victoria. Design and setting: Retrospective cohort study conducted by surveying doctors involved in managing incident ovarian cancer cases identified from the population‐based Victorian Cancer Registry. The survey was conducted in 1997 and the cohort was followed up until the end of 1999 to obtain at least four years of follow‐up data on all patients. Patients: All women with invasive epithelial ovarian cancer diagnosed during 1993, 1994 and 1995. Main outcome measures: Reported management in terms of staging, treatment and survival. Results: Management details were obtained for 84.5% (562/665) of eligible patients. Median age at diagnosis was 66 years (range, 22–98 years). Surgery was the primary therapy in 77.2% of women (434/562). Only one in three women had adequate surgery, which was less likely to be performed by general gynaecologists and general surgeons than gynaecological oncologists (21.3% [35/164] v 13.3% [8/60] v 52% [105/202]). After surgery 78.6% of women (341/434) received chemotherapy, usually with platinum‐based regimens. The overall five‐year relative survival was 46% for women treated surgically; poor survival was related to increasing age, later tumour stage, presence of ascites, residual disease > 2 cm and poorer histological differentiation of the tumour. Conclusions: For optimal care a preoperative carcinoma antigen (CA)‐125 assay, chest x‐ray and pelvic ultrasound should be performed, and early referral to a multi‐disciplinary unit for definitive surgery is advised. Every effort should be made to adequately stage or debulk the tumour. Women with high‐risk early‐stage and advanced disease should be considered for platinum‐based chemotherapy.